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ABSTRACT
Mesenchymal stem cells (MSCs) have been shown to amelio-
rate a variety of neurological dysfunctions. This effect is be-
lieved to be mediated by their paracrine functions, since these
cells rarely differentiate into neuronal cells. It is of clinical
interest whether neural induction of MSCs is beneficial for the
replacement therapy of neurological diseases. Here we report
that expression of Neurogenin1 (Ngn1), a proneural gene that
directs neuronal differentiation of progenitor cells during de-
velopment, is sufficient to convert the mesodermal cell fate of
MSCs into a neuronal one. Ngn1-expressing MSCs expressed
neuron-specific proteins, including NeuroD and voltage-gated
Ca2 and Na channels that were absent in parental MSCs.
Most importantly, transplantation of Ngn1-expressing MSCs
in the animal stroke model dramatically improved motor func-
tions compared with the parental MSCs. MSCs with Ngn1
populated the ischemic brain, where they expressed mature
neuronal markers, including microtubule associated protein 2,
neurofilament 200, and vesicular glutamate transporter 2, and
functionally connected to host neurons. MSCs with and with-
out Ngn1 were indistinguishable in reducing the numbers of
Iba1, ED1 inflammatory cells, and terminal deoxynucleoti-
dyl transferase dUTP nick-end labeling apoptotic cells and in
increasing the numbers of proliferating Ki67 cells. The data
indicate that in addition to the intrinsic paracrine functions of
MSCs, motor dysfunctions were remarkably improved by
MSCs able to transdifferentiate into neuronal cells. Thus, neu-
ral induction of MSCs is advantageous for the treatment of
neurological dysfunctions. STEM CELLS 2008;26:2217–2228
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INTRODUCTION
Mesenchymal stem cells (MSCs) are of clinical interest because
of their potential use in autologous transplantation, which is
attributable to their ability to improve a variety of dysfunctions
of a non-neurological, as well as neurological, nature [1]. The
critical question that remains unanswered is whether MSCs
should be genetically modified and tailored to be more effica-
cious for specific target organs and diseases. MSCs easily dif-
ferentiate into mesodermal tissues such as fat, bone, cartilage,
and muscle [2–4] but rarely into neuronal cells [5–7]. There
have been many attempts to induce trans-differentiation of
MSCs into neuronal cells [8, 9]. Unfortunately, most of these
studies suffered from artifacts created by in vitro chemical stress
[10, 11] or from misinterpretation of the in vivo transfer of
donor antigens from dying MSCs to host cells [12]. Therefore,
it still remains unclear whether neural-induced MSCs can serve
as better sources for replacement cell therapy of neurological
diseases. To address this, it will be necessary to develop a novel
strategy with minimal cellular stress and without loss of prolif-
eration capability.
Neurogenin1 (Ngn1) is a member of the basic helix-loop-
helix (bHLH) transcription factor family [13]. It is expressed in
early neuronal progenitor cells during development of the ner-
vous system [14–16]. Forced expression of Ngn1 has been
shown to increase the number of neuronal cells in Xenopus
embryos [13] and in uncommitted pluripotent stem cells, such as
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embryonic carcinoma P19 cells [17, 18], by activation of down-
stream proneural bHLH transcription factors, including NeuroD
[13]. Once NeuroD is expressed, the cells exit the cell cycle and
terminally differentiate into neurons. Meanwhile, Ngn1 sup-
presses astroglial differentiation by sequestering CREB binding
protein/p300 and Smad1 away from signal transducers and
activators of transcription-containing complexes that are re-
quired for glial fibrillary acidic protein (GFAP) expression [19].
In the present study, we show the neurogenic potential of
Ngn1 in converting the committed progenitor cells of non-
neural lineage, such as MSCs, into neuronal progenitor cells
without causing cellular stresses. We also show that neural
induction with Ngn1 dramatically enhances the therapeutic ef-
fects of MSCs for the treatment of stroke using an animal model.
Finally we provide evidence that higher motor recovery in
animals grafted with neural-induced MSCs is partly due to
transdifferentiation into neuronal cells in vivo.
MATERIALS AND METHODS
Preparation of MSC-Ngn1 Cells and In Vitro
Differentiation
Human mesenchymal stem cells were isolated from bone marrow
with approval of the Institutional Review Board of Ajou University
Medical Center. Cells were grown as adherent cultures in growth
medium (Dulbecco’s modified Eagle’s medium [DMEM] supple-
mented with 10% fetal bovine serum [FBS] and 10 ng/ml basic
fibroblast growth factor [bFGF]). Differentiation into mesoderm
cells was induced as described by Pittenger et al. [2]. The full-length
mouse Ngn1 cDNA (GenBank U63841) was inserted into the EcoRI
site of pMSCV-puro retroviral vector (Clontech, Palo Alto, CA,
http://www.clontech.com) with a FLAG epitope at the N terminus
to yield the retroviral vector pMSCV-puro/Ngn1. Retroviruses were
produced using a standard method by cotransfecting 293T cells with
pMSCV-puro/Ngn1 or pMSCV-puro/-galactosidase (-gal)
(Clontech) and gag- and env-expression vectors. For infections, the
MSCs were exposed three times to 1  106 particles of vesicular
stomatitis virus-glycoprotein pseudotyped retrovirus with 8 g/ml
polybrene (Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.
com) for 6 hours each time. After a 2-day incubation in growth
medium, the cells were split 1:20 into selection medium containing
puromycin (2 g/ml; Sigma-Aldrich). After 14 days, the surviving
cells were subcultured up to three or four passages for use in
experiments. To induce neuronal differentiation, cells were grown
on poly-D-lysine/collagen-coated culture dishes or coverslips in
growth medium containing 10 M 5-aza-deoxycytidine (Aza-dC;
Sigma-Aldrich) for 3 days and then in DMEM/F12 medium (In-
vitrogen, Carlsbad, CA, http://www.invitrogen.com) containing
10% FBS and 10 M forskolin (Sigma-Aldrich) for 14 days.
Immunocytochemistry
Cells were induced to differentiate on coverslips and fixed with 4%
paraformaldehyde (PFA) for 10 minutes. After blocking in normal
serum, the cells were incubated in 0.1% Triton X-100 in phosphate-
buffered saline (PBS) containing a primary antibody against micro-
tubule associated protein 2 ([MAP2]; monoclonal, 1:100; Sigma-
Aldrich), neurofilament 200 (NF200) (polyclonal, 1:200;
Chemicon, Temecula, CA, http://www.chemicon.com), and neuro-
nal nuclei (NeuN) (monoclonal, 1:100; Chemicon) at 4°C overnight.
Antibody reaction was visualized with Alexa Fluor 488-conjugated
anti-mouse or anti-rabbit secondary antibodies (Molecular Probes,
Eugene, OR, http://probes.invitrogen.com), and the cells were coun-
terstained with bis-benzimide (Molecular Probes). Epifluorescent
images were acquired with a Zeiss Axiophot microscope (Carl
Zeiss, Jena, Germany, http://www.zeiss.com).
Western Blot Analysis
Cells were lysed in SDS buffer (62.5 mM Tris-HCl, pH 6.8, 2%
SDS, 10% glycerol, and 50 mM dithiothreitol). Soluble proteins (30
g) were subjected to Western blot analysis using antibodies
against MAP2 (1:500) or GFAP (1:500) (Sigma-Aldrich), NF200
(1:1,000) or NeuN (1:500) (Chemicon), or -tubulin III (1:500)
(Covance, Richmond, CA, http://www.covance.com). The proteins
were probed with horseradish peroxidase-conjugated secondary an-
tibodies (Vector Laboratories, Burlingame, CA, http://www.
vectorlabs.com) and visualized using an enhanced chemilumines-
cence kit (Pierce, Rockford, IL, http://www.piercenet.com). Mouse
brain extracts (4 g) were used as controls.
Reverse Transcription Polymerase Chain Reaction
Total RNA was isolated using RNAzol B (Tel-Test, Friends-
wood, TX, http://www.isotexdiagnostics.com), and 1 g was
reverse-transcribed using a first-strand cDNA synthesis kit
(Roche Diagnostics, Basel, Switzerland, http://www.roche-
applied-science.com). The polymerase chain reaction (PCR)
primers were designed to span separate exons to eliminate pos-
sible DNA contamination. Forward and reverse primers were
GGCAGCGTTGGAACAGAGGTTGGA and CTCTAAACTGG-
AGTGGTCAGGGCT for Nestin, GCCCCAGGGTTATGAGA-
CTATCACT and GACAGAGCCCAGATGTAGTTCTT for
NeuroD, and CCACAGTCCATGCCATCACT and GAGCTTG-
ACAAAGTGGTCGT for glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). PCR was performed for 28 cycles for nestin
(60°C) and GAPDH (56°C) and for 33 cycles for NeuroD (58°C).
Electrophysiological Analyses
For Ca2 currents, the cells were differentiated as described above.
The bath solution was 150 mM NaCl, 5 mM KCl, 1.5 mM CaCl2,
1 mM MgCl2, 5 mM glucose, and 10 mM HEPES, and the pipette
solution was 90 mM cesium aspartate, 55 mM CsCl, 3 mM
Na2ATP, 3 mM Na2-creatine phosphate, 1 mM MgCl2, 10 mM
HEPES, and 10 mM EGTA, pH 7.4. For Na currents, the cells
were incubated in the presence of bFGF and epidermal growth
factor for 2 weeks. The bath solution was 140 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, and 10 mM
HEPES, and the pipette solution was 140 mM KCl, 5 mM NaCl, 1
mM CaCl2, 10 mM HEPES, 5 mM EGTA, and 2 mM Mg-ATP, pH
7.3. The electric currents were amplified using either an Axo-
patch-1C patch-clamp amplifier or Axopatch 200B patch-clamp
amplifier (Axon Instruments/Molecular Devices Corp., Foster City,
CA, http://www.moleculardevices.com). The signals were ampli-
fied with and digitized by an analog-to-digital interface (Gould
1425 [Gould Instruments, Hainault, U.K., http://www.lds-group.
com] or Digidata 1320 [Axon Instruments]) and analyzed with the
Clampfit version 6.0.3 software package or pClamp8.2 (Axon In-
struments).
Ischemic Animal Model and Cell Transplantation
All animal protocols were approved by the institutional animal care
and use committee of Ajou University Medical School. Male
Sprague-Dawley rats (250 g) were anesthetized with intraperito-
neal (i.p.) administration of ketamine (75 mg/kg) and xylazine
hydrochloride (5 mg/kg). Transient middle cerebral artery occlusion
(MCAo) was induced using a method of intraluminal vascular
occlusion [20]. Rectal temperature was maintained at 37°C through-
out the surgical procedure, using an electronic temperature control-
ler linked to a heating pad (FHC, Bowdoinham, ME, http://www.
fh-co.com). Animals showing similar scores (e.g., remaining on the
Rotarod [Ugo Basile, Comerio, Italy, http://www.ugobasile.com]
for more than 300 seconds during pretraining but less than 10
seconds after surgery) and comparable infarct volumes in magnetic
resonance imaging (MRI) were selected and randomly grouped.
This way, we were able to scrupulously control the quality of
animals and minimize variations among experimental groups. Three
days after MCAo, 1.0  106 cells in a total fluid volume of 10 l
were intracranially transplanted into the striatum (anteroposterior
[AP], 0.5; mediolateral [ML], 2.5; dorsoventral [DV], 5.0) and
cortex (AP, 0.5; ML, 2.0; DV, 2.5) in the ipsilateral hemisphere
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using a stereotactic apparatus (David Kopf Instruments, Tujunga,
CA, http://www.kopfinstruments.com).
Sixty rats in total were directly used to obtain the final data
shown in this study: PBS (n  19), MSC-LacZ cells (n  19), and
MSC-Ngn1 cells (n  22) (supplemental online Table 1). Eight
animals in each group were used in monitoring the infarct volume
with MRI and the behavioral outcome (Fig. 2) and finally sacrificed
to determine transdifferentiation after 8 weeks (Fig. 6C–6H; sup-
plemental online Figs. 1, 2). Six animals per group were sacrificed
at week 2 to verify the survival of grafted cells and cell type-specific
differentiation (Fig. 6A, 6B). To count the immunoreactive cells to
antibodies against 5-bromo-2-deoxyuridine (BrdU), Ki67, terminal
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL), or
ED1, five animals per group were injected daily with BrdU (50
mg/kg in saline, i.p.) for 4 days and analyzed on day 7. The
remaining rats were used for neuronal tracing with fluorogold.
Three normal rats were used for transplantation of MSC-Ngn1 cells
expressing wheat germ agglutinin (WGA).
Fluorescent Immunohistochemistry
Rats were anesthetized with ketamine and perfused transcardially
with ice-cold 0.9% saline followed by 4% PFA at indicated time
after transplantation. Brains were removed, postfixed in 4% PFA
overnight, and then embedded in paraffin. Serial 6-m-thick paraf-
fin sections were deparaffinized and then placed in boiled citrate
buffer (pH 6.0) for 10 minutes. After blocking in 1% bovine serum
albumin (BSA) and 5% normal serum, the sections were incubated
with antibodies against FLAG epitope (1:100), MAP2 (1:100),
NF200 (1:200), and GFAP (1:200) (Sigma-Aldrich); NeuN (1:100),
human mitochondria (1:100), and vesicular glutamate transporter 2
(VGLUT2; 1:100) (Chemicon); -galactosidase (1:100) (AbD Se-
rotec, Raleigh, NC, http://www.ab-direct.com); human Tau (1:50)
(Pierce); or synapsin I (1:50) (Abcam, Cambridge, U.K., http://
www.abcam.com) at 4°C overnight. Then, the sections were incu-
bated with Alexa Fluor 488- or 594-conjugated anti-IgG secondary
antibodies and counterstained with bis-benzamide (Molecular
Probes) to visualize the entire population of cells. Fluorescent
images were acquired using a Zeiss LSM510 confocal microscope
(Carl Zeiss). To increase the confidence in the colocalization anal-
ysis, care was taken to collect potentially overlapping emissions
separately using the “multitrack” function. For orthogonal projec-
tions, a stack of 20–30 confocal images that were 0.25 m apart
were typically collected and analyzed. To verify the survival of
grafted cells and cell type-specific differentiation, the numbers of
-galactosidase-expressing MSCs-LacZ or FLAG-tagged MSC-
Ngn1 cells were analyzed in the ischemic boundary zone. In each
animal, approximately 100 grafted cells were analyzed for cell
type-specific differentiation (NeuN or GFAP) by confocal micros-
copy. All counts were performed using split-panel and z-axis anal-
yses, and multichannel configuration was performed with a 40
objective. Each cell was examined in its full z-dimension, and only
cells with a grafted cell-specific marker unambiguously associated
with a lineage-specific marker were scored as positive.
Stereological Quantification
Five animals in each group were daily injected with BrdU (50
mg/kg in saline, i.p.) for 4 days after transplantation at day 3 until
sacrifice at day 7. To determine the total numbers of the BrdU-,
Ki67-, TUNEL-, ED1-positive cells in the subventricular zone
(SVZ) or ischemic territory, 50-m-thick frozen sections were
prepared from ischemic central lesion (anteroposterior, 1.2 mm
0.8 mm from bregma). To detect BrdU incorporation, sections
were pretreated with 2 N HCl at 37°C for 30 minutes and neutral-
ized with 0.1 M sodium borate (pH 9.0) for 10 minutes. The sections
were incubated in PBS containing 1% H2O2 for 20 minutes and then
in 1% BSA and 5% normal serum for 1 hour at room temperature.
The sections were probed with a mouse monoclonal anti-BrdU
antibody (1:200; Sigma-Aldrich) at 4°C overnight. To further verify
proliferating cells, sections were probed with anti-Ki67 antibody
(1:200; Chemicon). Apoptotic cells were analyzed with the In Situ
Cell Death Detection Kit, peroxidase (Roche Diagnostics), accord-
ing to the manufacturer’s instructions. To determine the infiltration
of inflammatory cells, the sections were probed with an anti-ED1
antibody (1:200; Serotec Ltd., Kidlington, U.K., http://www.
serotec.com). Then the antibody reactions were visualized using an
ABC kit (Vector Laboratories). Briefly, after washing the primary
antibody, the sections were sequentially incubated with biotinylated
goat anti-mouse secondary antibody (1:200 dilution; Vector Labo-
ratories) for 1 hour and avidin-peroxidase conjugate (Vector Lab-
oratories) solution for 30 minutes. The horseradish peroxidase re-
action was detected with 0.05% diaminobenzidine and 0.03% H2O2
in 50 mM Tris-HCl (pH 7.0). The sections were dehydrated through
graded alcohols, cleared in xylene, and coverslipped in permanent
mounting medium (Vector Laboratories).
After staining with each indicated antibodies, the sections were
analyzed with the Computer-Assisted Stereological Toolbox sys-
tem, version 2.1.4 (Olympus, Ballerup, Denmark, http://www.
olympus-global.com), equipped with an Olympus BX51 micro-
scope, a motorized microscope stage (Prior Scientific, Rockland,
MA, http://www.prior.com) run by an IBM-compatible computer,
and a microcator (ND 281B; Heidenhain, Traunreut, Germany,
http://www.heidenhain.com) connected to the stage and feeding the
computer with the distance information in the z-axis as previously
described [21]. The SVZ or ischemic territory was delineated using
a 1.25 objective and generated counting grid of 100  100 m or
300 300 m. An unbiased counting frame of known area (48.6
36.1 m  1,754 m2) superimposed on the image was placed
randomly on the first counting area and systemically moved through
all counting areas until the entire delineated area was sampled.
Actual counting was performed using a 100 oil objective. The
estimate of the total number of cells was calculated according to the
optical fractionator formula [22]. More than total 200 points over all
sections of each specimen were analyzed.
Neuronal Tracing
MSC-Ngn1 cells were transduced with WGA-expressing adenovi-
rus (multiplicity of infection  100), and 24 hours later 5  105
cells were transplanted into the right hippocampus of the normal rat
brain (AP, 3.5; ML, 2.0 mm; DV 3.0). Eight weeks later, the
animals were sacrificed and examined for the presence of grafted
MSC-Ngn1 cells using antibodies against human mitochondria or
WGA (1:100; Vector Laboratories). Double immunofluorescent
staining was carried out as described above using Alexa Fluor 488-
or 594-conjugated anti-IgG as secondary antibodies and counter-
staining with bis-benzamide (Molecular Probes).
Alternatively, 4 weeks after transplantation into the ischemic
brain, 1 l of fluorogold (FG; 2% solution in sterile saline; Molec-
ular Probes) was stereotactically injected into two sites of the
contralateral hemisphere (AP, 0.5; ML, 3.0; DV, 3.0 and AP, 0.5;
ML, 5.0; DV, 5.0). One week later, the animals were sacrificed
and analyzed for localization of FG using a confocal microscope.
MRI and Measurement of Infarct Volume
MRI scanning was performed using a 3.0-tesla whole-body MRI
scanner (Magnus 3.0; Medinus Inc., Yongin, South Korea, http://
www.medinus.co.kr) equipped with a gradient system capable of 35
milliteslas/m. A fast-spin echo imaging sequence was used to ac-
quire T2-weighted anatomical images of the rat brain in vivo, using
the following parameters: repetition time, 4,000 milliseconds; ef-
fective echo time, 96 milliseconds; field of view, 55  55 mm2;
image matrix, 256  256; slice thickness, 1.5 mm; flip angle, 90°;
number of excitations, 2; pixel size, 0.21  0.21 mm2. A 300-mm-
diameter quadrature 16-rung birdcage coil arrangement was used for
RF excitation, and a 40-mm-diameter saddle coil was used for signal
detection. A total of 15 slices were scanned to cover the whole rat brain.
Ischemic area from each T2-weighted image was marked manually and
calculated using the program Osiris (University of Geneva, http://www.
sim.hcuge.ch/osiris/01_Osiris_Presentation_EN.htm). The relative in-
farct volume (RIV) was normalized as described by Neumann-Haefelin
et al. [23] using the equation RIV [LT (RT RI)] d, where LT
and RT represent the areas of the left and right hemispheres, respec-
tively; RI is the infracted area; and d is the slice thickness (1.5 mm).
Relative infarct volumes (% HLV) were expressed as a percentage of
the right hemispheric volume.
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Motor Function Evaluation
Animals were pretrained for 1 week. In the Rotarod motor test, the
Rotarod cylinder was accelerated from 4 to 40 rpm within 5 min-
utes, and the cutoff time was 300 seconds. For adhesive removal
tests, square dots of adhesive-backed paper (100 mm2) were used as
bilateral tactile stimuli occupying the distal-radial region on the
wrist of each forelimb. Animals were given three trials with a cutoff
time of 300 seconds. The data are presented as the mean time to
remove the left dot. The neurological severity scores (NSS) were
calculated according to Li et al. [24], with a slight modification
(supplemental online Table 2). NSS tests were composed of the
reflex, posture, proprioception, and beam balance tests. Points were
awarded for the inability to perform a given test; thus, higher scores
represent more severe injury.
Statistical Analysis
Results were analyzed using one-way or repeated measures anal-
ysis of variance with independent variables of treatment groups
and days of testing, followed by Scheffe´’s post hoc test for
multiple comparisons at each treatment group. The level of
statistical significance was set at p  .05. All values are pre-
sented as the mean  SD.
Figure 1. In vitro differentiation of MSC-Ngn1 cells. Cells were induced to differentiate into mesodermal (A) or neural (B–F) cells as described
in Materials and Methods. (A): MSC-LacZ cells differentiated into adipocytes (oil red), osteocytes (alkaline phosphatase), and chondrocytes
(Alcian Blue). MSC-Ngn1 cells showed only very low levels of alkaline phosphatase activity. (B): Immunocytochemistry revealed expression of
NF200, MAP2, and NeuN (green) in MSC-Ngn1 cells but not in MSC-LacZ cells. Nuclei were counterstained with bis-benzimide (blue). Scale bars
50 m (A, B). (C): Western blot analysis showed expression of NF200, MAP2, and NeuN in MSC-Ngn1 cells but absence of those proteins in
MSC-LacZ cells. Positive controls () were mouse brain extracts. Note that III was expressed in both MSC-LacZ and MSC-Ngn1 cells, whereas
GFAP was not detected at all. (D): Reverse transcription polymerase chain reaction analysis showed that NeuroD was moderately expressed in
MSC-Ngn1 cells cultured in growth medium (Undiff) and further increased after terminal differentiation in the presence of 5-aza-deoxycytidine for
3 days and forskolin for 5 days (Diff). (E, F): MSC-Ngn1 cells were depolarized by step pulses from 60 to 40 mV at a holding potential of 70
mV. (E): Outward and inward currents were elicited simultaneously, and the inward currents through voltage-gated Ca2 channels could be reversibly
blocked by 4 M Nic. The peak inward currents were plotted against the voltages. (F): Voltage-gated Na currents were activated from a depolarizing
step of 40 mV and blocked reversibly by 1 M TTX. Peak current-voltage relationship was plotted against the voltages. Abbreviations: III,
-tubulin III; Diff., differentiated; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFAP, glial fibrillary acidic protein; MAP2, microtubule
associated protein 2; ms, milliseconds; MSC, mesenchymal stem cell; NF200, neurofilament 200; Ngn1, Neurogenin1; Nic., nicardipine; TTX,
tetrodotoxin; Undiff., undifferentiated.
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RESULTS
Neural Induction of MSCs with Ngn1
Human bone marrow MSCs stably expressing Ngn1, MSC-
Ngn1 cells, were obtained by transducing MSCs with Ngn1-
expressing retrovirus. MSC-Ngn1 cells continuously prolifer-
ated in growth medium without apparent morphological changes
but lost the potential to differentiate into adipocytes, chondro-
cytes, and osteocytes under conditions in which MSC-LacZ
cells, -galactosidase-expressing MSCs, easily differentiated
into these mesodermal cell types (Fig. 1A). Following terminal
differentiation with Aza-dC and forskolin, MSC-Ngn1 cells
expressed neuron-specific proteins, including NF200, MAP2,
and NeuN, as shown by both immunocytochemistry and West-
ern analyses (Fig. 1B, 1C). Importantly, after terminal differen-
tiation for 8 days, MSC-Ngn1 cells expressed NeuroD, a well-
known target gene of Ngn1 in terminally differentiating neurons
[13] (Fig. 1D). Under the same conditions, these proteins were
not detected or very minimally expressed in MSC-LacZ cells.
Moreover, 59% of MSC-Ngn1 cells (16 of 27 cells) exhibited
voltage-gated Ca2 currents with typical bell shaped current-
voltage curves that could be selectively blocked by 4 M
nicardipine, an L-type Ca2 channel blocker (Fig. 1E), and 75%
(15 of 20 cells) exhibited voltage-gated Na currents, of which
77% could be blocked by 1 M tetrodotoxin (Fig. 1F). In
contrast, none of the tested MSC-LacZ cells (n  53) exhibited
Ca2 currents, or less than 20% exhibited Na2currents that
were barely detectable (10 pA). These results indicate that
MSC-Ngn1 cells acquired neuronal cell fate and thereby ex-
pressed neuron-specific phenotypes after being terminally dif-
ferentiated in vitro.
Therapeutic Effects of MSC-Ngn1 Cells in a Rat
Stroke Model
We tested whether neural induction further enhanced the inher-
ent effects of MSCs for the treatment of neurological dysfunc-
tions. After inducing ischemic stroke in rats by MCAo, we
transplanted 5  105 cells each to two sites of the ischemic
boundary zones 3 days after reperfusion and analyzed motor
functions with Rotarod, adhesive removal, and NSS tests (Fig.
2A–2C). The control animals that received PBS spontaneously
recovered to a limited degree for 2 weeks and then reached a
plateau. Animals grafted with MSC-LacZ cells showed higher
recoveries than controls over the first 2 weeks, and the perfor-
mance scores remained constant thereafter. The animals with
MSC-Ngn1 cells exhibited the highest recovery among the
tested animals and continued to recover for up to 8 weeks even
after the other two groups ceased to recover. At 8 weeks,
compared with MSC-LacZ cells, MSC-Ngn1 cells showed 1.6-
fold higher scores in the Rotarod test (75%  8.1% vs. 45% 
7.4%), 3.6-fold lower scores in the adhesive removal test (21 
13.4 vs. 76  34.7 seconds), and 2.5-fold lower scores in
modified neurological severity score test (2  0.7 vs. 5  0.6
points). Our data of moderate functional recovery with MSC-
LacZ cells are in good agreement with previous studies [25].
The dramatic enhancement with MSC-Ngn1 cells is due to
neural induction.
We monitored the structural integrity of the brains using
MRI analysis over the 8-week experimental period. The hyper-
intense areas in T2-weighted images over the central eight
Figure 2. Effects of transplantation on re-
covery in the middle cerebral artery occlu-
sion animal model. (A–C): Performance in
the Rotarod (A), adhesive removal (B), and
mNSS (C) tests from 1 to 56 days after
ischemia. The data were collected from eight
animals per group and are presented as mean
values  SD. (D): The brain integrity of
each animal was monitored by magnetic res-
onance imaging from 3 to 56 days after
ischemia, and results are summarized in (E).
(E): The data are presented as mean relative
infarct volume  SD. (F): Cresyl violet
staining at 56 days after ischemia. The isch-
emic core is marked with . Scale bar  100
m. Statistically significant differences be-
tween the groups were determined by anal-
ysis of variance (, p  .05; , p  .01;
, p  .001 compared with the control
PBS group; #, p .05; ##, p .01; ###, p
.001 compared with the mesenchymal stem
cell-LacZ group). Abbreviations: mNSS,
modified neurological severity score; Ngn1,
Neurogenin1; PBS, phosphate-buffered sa-
line; sec., seconds.
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images (1.5-mm-thick section) were combined to obtain the
infarct volume (Fig. 2D, 2E). The original infarct volume was
57%  4.8% of the intact contralateral hemisphere. In the PBS
group, the infarct decreased spontaneously to 32% 5.4% after
2 weeks and then remained constant up to 8 weeks. Transplan-
tation of MSC-Ngn1 cells reduced the infarct to 21%  2.7% at
2 weeks; it continued to decrease thereafter and reached 12.4% 
2.2% at 8 weeks. MSC-LacZ cells reduced the infarct to a lesser
degree compared with MSC-Ngn1 cells (24%  3.3% at 8
weeks). In PBS-injected animals, Nissl staining showed the
massive degeneration 8 weeks after ischemia (Fig. 2F), and
most NeuN cells and axon bundles in cortex and striatum were
lost (Fig. 3D, 3G). In the MSC group, degeneration of striatum
was less severe, and some NeuN cells were found in the
remaining medioventral part of the striatum (Fig. 3E, 3H).
Importantly, degeneration was the smallest in the MSC-Ngn1
group. In particular, overall structures of ventrolateral cortex
and lateral striatum were greatly preserved, NeuN cells were
found more frequently, and striatal axon bundles appeared less
degenerated (Fig. 3F, 3I). The data collectively indicate that the
higher recovery of motor functions observed in the MSC-Ngn1
group is possibly correlated to the higher tissue integrity of the
host brain.
Paracrine Effects of MSC-Ngn1 Cells on
Surrounding Tissues
It is known that MSCs produce bioactive cytokines that promote
neurogenesis of resident stem cells in the SVZ [26, 27] and
protect delayed cell death in the detrimental environment of
damaged tissues [28, 29]. Since both neurogenesis and apoptosis
are known to be prominent 1 week after ischemic injury [27,
30], we administered BrdU to animals daily for 4 days begin-
ning immediately after transplantation and sacrificed them at
day 7. As previously reported, the control group showed
moderate proliferation of progenitor cells in SVZ in response
to ischemic injury (Fig. 4, compare the numbers of BrdU
cells in the ipsilateral and contralateral SVZs). Compared
with the control, transplantation of MSC-LacZ and MSC-
Figure 3. Effects of cell transplantation against ischemic brain damages. Coronal sections of brain at the level of the striatum were immunostained
with anti-NeuN antibody to visualize the ischemic neuronal loss 8 weeks after middle cerebral artery occlusion. Loss of NeuN-positive cells in the
ipsilateral striatum was dramatically reduced by transplantation of mesenchymal stem cell (MSC)-Neurogenin1 cells (C, F, I) compared with
MSC-LacZ (B, E, H) or phosphate-buffered saline-treated control (A, D, G). (D–F): Higher magnification of areas marked in (A–C), respectively.
(G–I): Higher magnification of areas marked in (D–F), respectively. NeuN cells are indicated with arrows; striatal axon bundles are marked with
asterisks. Scale bars  500 m (A–F) and 100 m (G–I).
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Ngn1 cells further increased the number of BrdU cells by
1.6- and 1.5-fold, respectively, and the number of Ki67
cells by 1.9- and 1.7-fold (Fig. 4). The differences between
MSC-LacZ and MSC-Ngn1 cells were statistically insignifi-
cant, suggesting that both types of cells are equivalent in
promoting a neurogenesis in SVZ.
To determine the effect on the delayed cell death in the
penumbra regions such as ischemic boundary zone (IBZ) and
dorsolateral striatum (ST) (Fig. 5A), we carried out TUNEL
assays on the same animal brains. The control animals showed
massive apoptosis 1 week after ischemic injury. Transplantation
of MSC-LacZ and MSC-Ngn1 cells reduced the number of
TUNEL cells by 45% and 37% in IBZ, respectively, and by
48%–49% in ST (Fig. 5B, 5C). Again, the differences between
animals grafted with MSC-LacZ and MSC-Ngn1 cells were
insignificant.
Pathological changes following ischemia trigger inflamma-
tory responses, including activation of resident microglia and
infiltration of leukocytes into microvessels and ischemic cere-
bral parenchyma, which may cause subsequent damages to the
brain tissue [29]. Thus, we tested for differences in inflamma-
tory cells 4 days after transplantation using ED1 antibody (Fig.
5D–5E). ED1 recognizes CD68, a phagocytic cell marker for
active microglia, monocytes, and macrophages, and indicates
ongoing inflammation. The numbers of ED1 cells were re-
duced by 34% in IBZ and 41%–50% in ST in the animals with
MSC-LacZ and MSC-Ngn1 cells compared with the control
animals. Again, the differences between MSC-LacZ and
MSC-Ngn1 cells were insignificant. Taken together, our data
indicate that the immediate effects of parental MSCs and
MSC-Ngn1 cells on the host brain are indistinguishable and
suggest that neural induction of MSCs with Ngn1 may further
increase the functional recovery through a mechanism that is
yet unknown.
Transdifferentiation of MSC-Ngn1 Cells In Vivo
We sought evidence that the dramatic functional recovery in ani-
mals with MSC-Ngn1 cells was due, at least in part, to neuronal
differentiation of the transplanted cells. Evaluation of neuronal
differentiation of grafted cells in vivo was performed carefully,
since small chemicals such as Hoechst or BrdU can be transferred
from donor to host cells [12, 31] and autofluorescence can be
emitted from dying cells [12]. We identified MSC-LacZ cells with
anti--gal antibody and MSC-Ngn1 cells with anti-FLAG antibody
in addition to anti-human mitochondrial antibody to avoid possible
misinterpretation of donor-to-host cell transfer of labeling. Two
weeks after transplantation, MSC-LacZ cells were found in IBZ, of
which 21% were GFAP, whereas 79% remained undifferentiated.
NeuN cells were scarcely found (Fig. 6A). Thereafter, these cells
gradually disappeared and were barely detectable 4 weeks after
transplantation. At 2 weeks, MSC-Ngn1 cells could be found in
both cortical core and IBZ, where more than 45% of them differ-
entiated NeuN cells, whereas 55% remained undifferentiated.
GFAP cells were seldom found (Fig. 6B). Importantly, unlike
MSCs, many of the MSC-Ngn1 cells survived through the full
8-week experimental period and became NeuN and MAP2 (Fig.
6C–6H). These cells exhibited morphology of mature neurons with
long processes and expressed functional neuronal proteins such as
VGLUT2 (Fig. 6E), as well as NF200 (an intermediate filament
protein found in thick and thin axons of neuron) and tau (a neural
microtubule-associated protein), which are found in mature neu-
rons (supplemental online Figs. 1, 2). Moreover, expression of
synapsin I (a presynaptic neuron-specific phosphoprotein) was
colocalized with axon-like structures of these cells, suggesting
synapse formation between host neurons (presynpatic) and MSC-
Ngn1 cells (postsynaptic).
To determine whether these cells were functionally connected
to host neural networks, we performed tracing experiments with
two independent approaches. First, we injected a retrograde tracer,
Figure 4. Effects of grafted cells on endogenous neurogenesis. (A): BrdU or Ki67 neural progenitor cells in the SVZ were increased by
transplantation of mesenchymal stem cell (MSC)-LacZ or MSC-Ngn1 cells compared with PBS-treated controls. (B, C): Quantitative analysis of
BrdU (B) or Ki67 (C) cells in the SVZ of Ipsi hemisphere (filled) and Contra hemisphere (open). Data from five animals are presented as mean
values  SD. Both MSC-LacZ and MSC-Ngn1 groups showed significant differences from the control PBS group (analysis of variance; , p  .05).
Scale bars  100 m. Abbreviations: BrdU, 5-bromo-2-deoxyuridine; Contra, contralateral; Ipsi, ipsilateral; Ngn1, Neurogenin1; PBS, phosphate-
buffered saline; SVZ, subventricular zone.
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FG [32–34], into the contralateral corpus callosum of the ischemic
brain 4 weeks after transplantation and sacrificed the animals at 5
weeks. The grafted cells with a human mitochondria antigen in the
ischemic hemisphere were found to contain the FG label (Fig.
7A–7C), indicating that the FG had been transported from the host
neurons through the synapses and taken up by MSC-Ngn1 cells.
Second, we engineered MSC-Ngn1 cells to express WGA in vitro
and then transplanted them in the hippocampus of normal rat
brains. WGA is known to be transported bidirectionally to axons
and dendrites and taken up by pre- and postsynaptic neurons [35].
Eight weeks after transplantation, we found WGA not only in the
grafted MSC-Ngn1 cells (Fig. 7E, 7F) but also in the soma and
axons of the host hippocampal neurons in the contralateral hemi-
sphere (Fig. 7G, 7H) of all tested animals (n 3). The data clearly
indicate that MSC-Ngn1 cells terminally differentiate into mature
neurons in vivo and functionally connected to the host’s neuronal
networks.
DISCUSSION
Stem cell therapy has emerged as an exciting candidate for the
treatment of neurological diseases. Among the various types of
stem cells, MSCs are of particular clinical interest because they
can be isolated from bone marrow, adipose tissues, and umbil-
ical cord blood. MSCs were shown to improve the neurological
dysfunctions in stroke patients [36]. The present study presents
the scientific basis for a requirement of neural induction of
MSCs for better treatment of neurological dysfunctions.
During development of the nervous system, Ngn1 directs
neural precursor cells to acquire neuronal cell fates by activating
a series of downstream proneural bHLH transcription factors,
such as Nex1, NeuroM, and NeuroD/BETA2 [13], while sup-
pressing astroglial differentiation [19]. Surprisingly, overex-
pression of Ngn1 in MSCs is sufficient to convert their meso-
dermal cell fate to a neuronal one. The expression of NeuroD
was increased when MSC-Ngn1 cells were challenged to exit
the cell cycle and terminally differentiate by treatment with
forskolin and Aza-dC (Fig. 1D), which is in good agreement
with previous report that NeuroD causes cell cycle exit in
terminally differentiating neurons [37, 38].
We have previously shown that treatment of forskolin alone
in the presence of low serum may facilitate neuronal differen-
tiation, which, however, is not sufficient to induce expression of
voltage-gated ion channels [39], nor can cotreatment of forsko-
lin with Aza-dC in the presence of high serum induce expression
of voltage-gated Ca2 or Na channels in MSCs as in this
study. In contrast, these channels were easily detected in termi-
nally differentiated MSC-Ngn1 cells (Fig. 1E, 1F) along with
other neuronal markers, such as MAP2, NF200, and NeuN (Fig.
1B, 1C). Voltage-gated L-type Ca2 channels and tetrodotoxin-
sensitive voltage-gated Na channels are critical elements for
initiation and propagation of action potential in neurons [40].
Thus, expression of these channels indicates that MSCs acquire
neuron-like membrane excitability under the influence of Ngn1.
Taken together, our results indicate that MSC-Ngn1 cells trans-
differentiate into neuronal cells in vitro and that the emergence
of neuronal characteristics in MSC-Ngn1 cells is not the result
of the simple cytoskeletal rearrangement caused by cellular
stress [10, 11] but rather is due to acquisition of neuronal cell
fates.
After being transplanted, both MSC-LacZ and MSC-
Ngn1 cells survived to a similar extent for 2 weeks in the
brain parenchyma without treatment of immune suppressants.
Transplanted human MSCs can survive preferentially in in-
jury sites following MCAo [24, 41– 43] and brain trauma [44]
without any immune suppressants. Escape from the immune
surveillance during the early period is partly due to the fact
that MSCs lack MHC class II or costimulatory molecules
such as CD40, CD80, and CD86 [45– 47] or secrete inhibitory
molecules against xenograft rejection [48, 49]. In a 2-week
period, surviving MSCs either took GFAP astrocytic cell
fates or remained undifferentiated. MSCs grown in our cul-
ture conditions seldom became NeuN cells in vivo and
almost disappeared in 4 weeks. Our result of short-term
survival of MSCs is in good agreement with the previous
reports that transplanted MSCs cannot survive for an ex-
tended period of time, and only a very limited number of
them, as low as 1%–2%, typically differentiate into neuronal
cells [50, 51]. In contrast, MSC-Ngn1 cells survived up to 8
weeks and probably even longer in the pathogenic environ-
ment. These cells expressed functional neuronal proteins
such as VGLUT2 (Fig. 6E), NF200, synapsin I, and tau,
which are found in mature neurons (supplemental online
Figs. 1, 2). The prolonged survival of MSC-Ngn1 cells may
be partly due to the consequence of transdifferentiation into
neurons and their connectivity to the host neurons. During
development, target cells send neurotrophic signals retro-
gradely over long distances to presynaptic neuronal cell
bodies and then selectively promote the survival of presyn-
aptic neurons and maintenance of proper neural connectivity
Figure 5. Effects of grafted cells on cell death and inflammation. (A): The
ischemic brain, schematically illustrated: CC, IBZ (1), and ST (2). The
numbers of TUNEL cells (B) and ED1 cells (D) in the ipsilateral IBZ,
and ST are illustrated. (C, E): Data are presented as mean numbers of
positive cells SD. Note that the numbers of TUNEL or ED1 cells were
decreased by transplantation of mesenchymal stem cell (MSC)-LacZ or
MSC-Ngn1 cells compared with PBS-injected control. Both MSC-LacZ
and MSC-Ngn1 groups showed significant differences from the control
PBS group in the IBZ and ST (analysis of variance; , p  .05). Scale
bars  20 m. Abbreviations: CC, cortical core; IBZ, ischemic boundary
zone; Ngn1, Neurogenin1; PBS, phosphate-buffered saline; ST, striatum;
TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.
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while excess neurons that fail to form functional synapse are
pruned out [52]. Indeed, MSC-Ngn1 cells established a con-
nection to the host neurons located in the contralateral hemi-
sphere, as shown by transport of WGA or FG (Fig. 7).
Collectively, these results suggest that MSC-Ngn1 cells ter-
minally differentiate into functional neurons in vivo and, in
return, survive for an extended period of time.
During cortical development, Ngn1 and Ngn2 are ex-
pressed in dorsal progenitors in the telencephalon, which give
rise to cortical glutamatergic pyramidal neurons [53]. A
forced expression of Ngn2 specifies neural stem cells of the
adult subependymal zone to differentiate into glutamatergic
neurons, whereas overexpression of Mash1 causes cells to
differentiate into GABAergic neurons [54], suggesting that
bHLH proneural genes function to instruct cell type specifi-
cation, as well as directing cell fate determination. In our
study, MSC-Ngn1 cells spontaneously differentiated into
VGLUT2 glutamatergic neurons in vivo (Fig. 6E) but rarely
became GFAP astrocytes (Fig. 6), suggesting that Ngn1
directs MSCs to acquire the glutamatergic neuronal cell fate,
as it does during embryonic brain development. Additional
studies with more bHLH transcription factors, particularly
Mash1, will answer whether the bHLH factors, as in neural
stem cells, also guide cell type specification in MSCs while
instructing neuronal cell fates.
Previously it has been shown that activation of Notch sig-
nals together with application of bFGF, forskolin, and ciliary
neurotrophic factor could induce neuronal differentiation of
MSCs [55]. During development of the nervous system, Notch
is known to repress neuronal differentiation of neural progenitor
cells [56] and trigger differentiation of glial cells, including
radial glia [57], Schwann cells [58], Mu¨ller cells in retina [59],
and astrocytes [60, 61]. These functions of Notch are mediated
by J recombination signal-binding protein (RBP-J) or C-
promoter-binding factor-1, which subsequently downregulates
the proneural genes, including Ngn1 [62]. Therefore, one of the
issues in need of clarification is how the apparently opposing
signals from Notch and Ngn1 can be reconciled with induction
of neuronal differentiation of MSCs.
Figure 6. In vivo differentiation of grafted
cells in the ischemic brain. (A, B): Confocal
images of the grafted cells at 2 weeks after
ischemia. MSC-LacZ and MSC-Ngn1 cells
were identified by the expression of cytoso-
lic -gal (A) (green) and nuclear FLAG (B)
(green), respectively. Glial fibrillary acidic
protein (red) was expressed in MSC-LacZ
cells (A), whereas NeuN (red) was ex-
pressed in MSC-Ngn1 cells (B). Arrowheads
denote the donor-derived cells (green) colo-
calized with cell type-specific antigens (red)
in enlarged orthographic images. (C–E):
Confocal images of the MSC-Ngn1 cells at 8
weeks after ischemia. Nuclei staining (blue)
shows scarce distribution of cells in the in-
farct region. MSC-Ngn1 cells (nuclear
FLAG, green) survived for more than 8
weeks and expressed NeuN (C) (red), MAP2
(D) (red), and VGLUT2 (E) (red). (F–H):
Enlarged orthographic images show colocal-
ization of NeuN (F) (perinucleus), MAP2
(G) (dendrite), or VGLUT2 (H) (axon) in
MSC-Ngn1 cells (green). Scale bars  20
m. Abbreviations: -gal, -galactosidase;
MAP2, microtubule associated protein 2;
MSC, mesenchymal stem cell; Ngn1, Neu-
rogenin1; VGLUT2, vesicular glutamate
transporter 2.
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Saving the penumbra, where the functions of neurons are
impaired but potentially viable, is the main target of acute
stroke therapy. Consistent with the remarkable recovery of
motor functions, the tissue integrity of penumbra regions
appears to be salvaged more rigorously by the MSC-Ngn1
cells than by MSC-LacZ cells; numerous NeuN cells were
found IBZ and ST, and striatal axon bundles remain less
damaged (Figs. 2F, 3). The marvelous rescue of penumbra
regions from the ischemic injury is the combinatorial results
of several functions: (a) immune suppression; (b) promotion
of neurogenesis; (c) protection from the delayed cell death of
host neurons and newly generated, migrating neuroblasts;
and (d) transdifferentiation. Following ischemic injury, qui-
escent microglias are activated to have round, enlarged soma
and macrophage-like characteristics. This traditional view of
microglia has been challenged by recent finding that many
Iba1 microglia undergo apoptotic degeneration in the lesion
core within 24 hours after brain ischemia [63]. Therefore, the
ED1 cells that we observed 1 week after reperfusion are
very likely to be infiltrated neutrophils and monocytes [64].
Overall, we could not find significant differences between
MSC-LacZ and MSC-Ngn1 cells in promoting neurogenesis,
suppressing delayed cell death, and modulating immune re-
sponses during the early time period. Therefore, the robust
recovery in animals with MSCs-Ngn1cells is attributed to
their transdifferentiation. Directly, transdifferentiated cells
are integrated into host neural circuits and replace the dam-
age host neurons. Indirectly, as we mentioned above, trans-
differentiated MSCs-Ngn1 cells survive for an extended pe-
riod of time and secrete beneficial factors in physiologically
regulated manners.
MSCs are currently being tested for their potential use in
cell therapy of a number of human diseases, in addition to stroke
[36], including neurological diseases (such as amyotrophic lat-
eral sclerosis), lysosomal storage diseases, and non-neurological
diseases (such as acute myocardial infarction, vascular resteno-
sis, osteogenesis imperfecta, steroid refractory graft-versus-host
disease, periodontitis, and bone fracture) [1]. Typical therapeu-
tic effects of MSCs are attributed to their paracrine function of
secreting bioactive substances. The critical question is answered
by the present study that these cells are more effective after
neural induction.
In summary, we have demonstrated that Ngn1 is sufficient
to induce neural cell fates in MSCs. The Ngn1-expressing MSCs
are comparable to neural stem cells (NSCs) in that they nestle
within the necrotic host parenchyma, become neuronally com-
mitted, and provide a source for cellular replacement [65]. As is
the case with NSCs, it is possible that the Ngn1-expressing
MSCs may secrete neurotrophic factors in a physiologically
regulated manner, potentially providing an additional benefit for
the reparative processes of host cells. As such, the present study
highlights the advantage of neural induction of MSCs, a stem
cell with a far greater accessibility than NSCs, in the develop-
ment of new strategies for treating central nervous system
dysfunctions.
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Figure 7. Neural tracing of transplanted
MSC-Ngn1 cells. (A): A schematic illustra-
tion shows transplantation of MSC-Ngn1 in
the ischemic brain and injection of FG in the
contralateral site (Materials and Methods).
(B): One week later, FG (green) was found
in MSC-Ngn1 cells (red) that were identified
with anti-hMt antibody. (C): An ortho-
graphic image of hMt, FG cells in (B).
(D): MSC-Ngn1 cells were prelabled with
WGA and transplanted into hippocampus of
the normal brain. (E): Eight weeks later,
MSC-Ngn1 cells were found to be hMt
(green) and WGA (red). (F): An ortho-
graphic image of hMt, WGA cells in (E).
(G): Host neurons in the contralateral hip-
pocampus were devoid of hMt and colocal-
ized with WGA (red). Note the prominent
WGA nerve endings (red) in the hippocam-
pus. (H): An orthographic image of the
WGA host neuron in (G). Scale bars  20
m. Abbreviations: FG, fluorogold; hMt,
human mitochondria; MSC, mesenchymal
stem cell; Ngn1, Neurogenin1; WGA, wheat
germ agglutinin.
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